The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy
Open accessAbstract
Anthracycline-based chemotherapy can result in the development of a cumulative and progressively developing cardiomyopathy. Doxorubicin is one of the most highly prescribed anthracyclines in the United States due to its broad spectrum of therapeutic efficacy. Interference with different mitochondrial processes is chief among the molecular and cellular determinants of doxorubicin cardiotoxicity, contributing to the development of cardiomyopathy. The present review provides the basis for the involvement of mitochondrial toxicity in the different functional hallmarks of anthracycline toxicity. Our objective is to understand the molecular determinants of a progressive deterioration of functional integrity of mitochondria that establishes a historic record of past drug treatments (mitochondrial memory) and renders the cancer patient susceptible to subsequent regimens of drug therapy. We focus on the involvement of doxorubicin-induced mitochondrial oxidative stress, disruption of mitochondrial oxidative phosphorylation, and permeability transition, contributing to altered metabolic and redox circuits in cardiac cells, ultimately culminating in disturbances of autophagy/mitophagy fluxes and increased apoptosis. We also suggest some possible pharmacological and nonpharmacological interventions that can reduce mitochondrial damage. Understanding the key role of mitochondria in doxorubicin-induced cardiomyopathy is essential to reduce the barriers that so dramatically limit the clinical success of this essential anticancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,733
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network
Scarpulla, R. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.09.019 · Cited by 1,281
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
The anthracyclines: will we ever find a better doxorubicin?
Weiss, R. B. (1992) · PubMed · Cited by 918
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., Mutharasan, R. K., Naik, T. J., & Ardehali, H. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72931 · Cited by 878
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Transcriptional integration of mitochondrial biogenesis
Scarpulla, R. C., Vega, R. B., & Kelly, D. P. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.006 · Cited by 798
Autosis and autophagic cell death: the dark side of autophagy
Liu, Y., & Levine, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.143 · Cited by 742
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Broekemeier, K. M., Dempsey, M. E., & Pfeiffer, D. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83116-7 · Cited by 699
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
The potential diagram for oxygen at pH 7
Wood, P. M. (1988) · Biochemical Journal · doi:10.1042/bj2530287 · Cited by 649
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Mitochondrial permeability transition in Ca2+-dependent apoptosis and necrosis
Rasola, A., & Bernardi, P. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.04.007 · Cited by 563
Doroshow, J. H., & Davies, K. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 540
Hoshino, A., Mita, Y., Okawa, Y., Ariyoshi, M., Iwai-Kanai, E., Ueyama, T., Ikeda, K., Ogata, T., & Matoba, S. (2013) · Nature Communications · doi:10.1038/ncomms3308 · Cited by 536
Childs, A. C., Phaneuf, S., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002) · PubMed · Cited by 525
Energetics, epigenetics, mitochondrial genetics
Wallace, D. C., & Fan, W. (2010) · Mitochondrion · doi:10.1016/j.mito.2009.09.006 · Cited by 505
Nuclear Receptor Signaling and Cardiac Energetics
Huss, J. M., & Kelly, D. P. (2004) · Circulation Research · doi:10.1161/01.res.0000141774.29937.e3 · Cited by 473
Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification
Li, D. L., Wang, Z. V., Ding, G., Tan, W., Luo, X., Criollo, A., Xie, M., Jiang, N., May, H., Kyrychenko, V., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017443 · Cited by 464
Cytochrome c/cardiolipin relations in mitochondria: a kiss of death
Kagan, V. E., Bayır, H. A., Belikova, N. A., Kapralov, O., Tyurina, Y. Y., Tyurin, V. A., Jiang, J., Stoyanovsky, D. A., Wipf, P., Kochanek, P. M., et al. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.03.004 · Cited by 444
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 420
Zhao, L., & Zhang, B. (2017) · Scientific Reports · doi:10.1038/srep44735 · Cited by 375
Antioxidant nutrients and adriamycin toxicity
Quiles, J. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00383-9 · Cited by 362
The Turnover of Mitochondria in a Variety of Tissues of Young Adult and Aged Rats
Menzies, R. A., & Gold, P. H. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)62305-1 · Cited by 336
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5841 · Cited by 335
Early anthracycline cardiotoxicity
Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., & Harrison, D. C. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90802-1 · Cited by 334
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.
Zhou, S., Starkov, A. A., Froberg, M. K., Leino, R. L., & Wallace, K. B. (2001) · PubMed · Cited by 314
Self-citationAutophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
Koleini, N., & Kardami, E. (2017) · Oncotarget · doi:10.18632/oncotarget.16944 · Cited by 301
Early and delayed clinical cardiotoxicity of doxorubicin
Buzdar, A. U., Marcus, C., Blumenschein, G. R., & Smith, T. L. (1985) · Cancer · doi:10.1002/1097-0142(19850615)55:12<2761::aid-cncr2820551206>3.0.co;2-p · Cited by 300
Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte Death
Kobayashi, S., Volden, P., Timm, D., Mao, K., Xu, X., & Liang, Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.070037 · Cited by 284
Humanin: a harbinger of mitochondrial-derived peptides
Lee, C., Yen, K., & Cohen, P. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.01.005 · Cited by 284
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).
Bonadonna, G., Monfardini, S., Lena, M. D., Fossati‐Bellani, F., & Beretta, G. (1970) · PubMed · Cited by 278
Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis
Das, K. P., Wood, C. R., Lin, M. T., Starkov, A. A., Lau, C., Wallace, K. B., Corton, J. C., & Abbott, B. D. (2017) · Toxicology · doi:10.1016/j.tox.2016.12.007 · Cited by 254
Self-citationKremer, L. C. M., van Dalen, E. C., Offringa, M., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf118 · Cited by 249
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review
Aubel-Sadron, G., & Londos-Gagliardi, D. (1984) · Biochimie · doi:10.1016/0300-9084(84)90018-x · Cited by 233
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.005 · Cited by 227
Self-citationClinical Evaluation of Adriamycin, a New Antitumour Antibiotic
Bonadonna, G., Monfardini, S., de Lena, M., & Fossati-Bellani, F. (1969) · BMJ · doi:10.1136/bmj.3.5669.503 · Cited by 220
Doxorubicin-induced persistent oxidative stress to cardiac myocytes
Zhou, S., Palmeira, C. M., & Wallace, K. B. (2001) · Toxicology Letters · doi:10.1016/s0378-4274(01)00329-0 · Cited by 219
Self-citationDhingra, R., Margulets, V., Chowdhury, S. R., Thliveris, J., Jassal, D., Fernyhough, P., Dorn, G. W., & Kirshenbaum, L. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414665111 · Cited by 217
Zhang, C., Feng, Y., Qu, S., Wei, X., Zhu, H., Luo, Q., Liu, M., Chen, G., & Xiao, X. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr022 · Cited by 213
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
Danesi, R., Fogli, S., Gennari, A., Conte, P., & Del Tacca, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00004 · Cited by 203
Structure of the adriamycin-cardiolipin complex
Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., & Ruysschaert, J.-M. (1990) · Biophysical Chemistry · doi:10.1016/0301-4622(90)80012-v · Cited by 200
Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults
Larsen, R. L., Jakacki, R. I., Vetter, V. L., Meadows, A. T., Silber, J. H., & Barber, G. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91393-i · Cited by 197
Abdullah, C. S., Alam, S., Aishwarya, R., Miriyala, S., Bhuiyan, M. A. N., Panchatcharam, M., Pattillo, C. B., Orr, A. W., Sadoshima, J., Hill, J. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37862-3 · Cited by 193
Yin, J., Guo, J., Zhang, Q., Cui, L., Zhang, L., Zhang, T., Zhao, J., Li, J., Middleton, A., Carmichael, P. L., et al. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.05.001 · Cited by 192
Arai, M., Yoguchi, A., Takizawa, T., Yokoyama, T., Kanda, T., Kurabayashi, M., & Nagai, R. (2000) · Circulation Research · doi:10.1161/01.res.86.1.8 · Cited by 189
Wang, X., Wang, X.-L., Chen, H.-L., Wu, D., Chen, J.-X., Wang, X.-X., Li, R.-L., He, J.-H., Mo, L., Cen, X., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.040 · Cited by 183
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., Gödtel-Armbrust, U., & Wojnowski, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-842 · Cited by 176
Zilinyi, R., Czompa, A., Czegledi, A., Gajtko, A., Pituk, D., Lekli, I., & Tosaki, A. (2018) · Molecules · doi:10.3390/molecules23051184 · Cited by 175
Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Santos, D. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9532 · Cited by 174
Acute arrhythmogenicity of doxorubicin administration
Steinberg, J. S., Cohen, A. J., Wasserman, A. G., Cohen, P., & Ross, A. M. (1987) · Cancer · doi:10.1002/1097-0142(19870915)60:6<1213::aid-cncr2820600609>3.0.co;2-v · Cited by 171
Doxorubicin Inactivates Myocardial Cytochrome c Oxidase in Rats: Cardioprotection by Mito-Q
Chandran, K., Aggarwal, D., Migrino, R. Q., Joseph, J., McAllister, D., Konorev, E. A., Antholine, W. E., Zielonka, J., Srinivasan, S., Avadhani, N. G., et al. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2008.10.042 · Cited by 170
Hollander, J. M., Thapa, D., & Shepherd, D. L. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00747.2013 · Cited by 167
Mitochondrial regulation of epigenetics and its role in human diseases
Minocherhomji, S., Tollefsbol, T. O., & Singh, K. K. (2012) · Epigenetics · doi:10.4161/epi.19547 · Cited by 163
Lass, A., & Sohal, R. S. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0606 · Cited by 161
Ascensão, A., Magalhães, J., Soares, J. M. C., Ferreira, R., Neuparth, M. J., Marques, F., Oliveira, P. J., & Duarte, J. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01249.2004 · Cited by 160
Self-citationSerrano, J., Palmeira, C. M., Kuehl, D. W., & Wallace, K. B. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00011-0 · Cited by 159
Self-citationTokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., SCHAUB, M. C., Wallimann, T., & Schlattner, U. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01057.2004 · Cited by 159
Jong, D. S., Zijlstra, J. G., de Vries, E. G. E., & Mulder, N. H. (1990) · PubMed · Cited by 159
Willis, M. S., Parry, T. L., Brown, D. I., Mota, R. I., Huang, W., Beak, J. Y., Sola, M., Zhou, C., Hicks, S. T., Caughey, M. C., et al. (2019) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.005234 · Cited by 159
Rosa‐Garrido, M., Chapski, D. J., Schmitt, A. D., Kimball, T. H., Karbassi, E., Monte, E., Balderas, E., Pellegrini, M. A., Shih, T.-T., Soehalim, E., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029430 · Cited by 155
Vercesi, A. E., Castilho, R. F., Kowaltowski, A. J., Oliveira, H. C. F., de Souza-Pinto, N. C., Figueira, T. R., & Busanello, E. N. B. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.08.034 · Cited by 152
Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models
Komen, J. C., & Thorburn, D. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12413 · Cited by 149
Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice
Shizukuda, Y., Matoba, S., Mian, O. Y., Nguyen, T., & Hwang, P. M. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-5905-8 · Cited by 148
Bartlett, J. J., Trivedi, P. C., Yeung, P. K. F., Kienesberger, P. C., & Pulinilkunnil, T. (2016) · Biochemical Journal · doi:10.1042/bcj20160385 · Cited by 145
Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity
Chicco, A. J., Hydock, D. S., Schneider, C. M., & Hayward, R. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00148.2005 · Cited by 144
Mitochondrial turnover in the heart
Gottlieb, R. A., & Gustafsson, Å. B. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.11.017 · Cited by 143
Gharanei, M., Hussain, A., Janneh, O., & Maddock, H. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077713 · Cited by 141
Xu, Z., Li, C., Liu, Q.-L., Li, P., & Yang, H. Q. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113658 · Cited by 138
PGC-1: The Energetic Regulator in Cardiac Metabolism
Di, W., Lv, J., Jiang, S., Lu, C., Yang, Z. P., Ma, Z., Hu, W., Yang, Y., & Xu, B. (2018) · Current Issues in Molecular Biology · doi:10.21775/cimb.028.029 · Cited by 137
Mitochondrial damage-associated molecular patterns and vascular function
Wenceslau, C. F., McCarthy, C. G., Szasz, T., Spitler, K., Goulopoulou, S., Webb, R. C., & Working Group on DAMPs in Cardiovascular Disease (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu047 · Cited by 135
Foote, K., Reinhold, J., Yu, E., Figg, N. L., Finigan, A. J., Murphy, M. P., & Bennett, M. R. (2018) · Aging Cell · doi:10.1111/acel.12773 · Cited by 132
Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy
Carvalho, R. A., Sousa, R. P. B., Cadete, V. J. J., Lopaschuk, G. D., Palmeira, C. M., Bjork, J. A., & Wallace, K. B. (2010) · Toxicology · doi:10.1016/j.tox.2010.01.019 · Cited by 131
Self-citationDisruption of Mitochondrial Calcium Homeostasis Following Chronic Doxorubicin Administration
Solem, L. E., Henry, T. R., & Wallace, K. B. (1994) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1994.1246 · Cited by 131
Self-citationProgrammed necrosis in heart disease: Molecular mechanisms and clinical implications
Zhu, H., & Sun, A. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.01.018 · Cited by 130
Left Ventricular Mass Change After Anthracycline Chemotherapy
Jordan, J. H., Castellino, S. M., Meléndez, G. C., Klepin, H. D., Ellis, L. R., Lamar, Z. S., Vasu, S., Kitzman, D. W., Ntim, W. O., Brubaker, P. H., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004560 · Cited by 130
Muoio, D. M., & Koves, T. R. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h07-083 · Cited by 129
Kavazis, A. N., Smuder, A. J., & Powers, S. K. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00210.2014 · Cited by 123
Kirkham, A. A., Eves, N. D., Shave, R., Bland, K. A., Bovard, J. M., Gelmon, K. A., Virani, S., McKenzie, D. C., Stöhr, E. J., Waburton, D. E. R., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4554-4 · Cited by 117
Transcription factor GATA4 regulates cardiac BCL2 gene expression in vitro and in vivo
Kobayashi, S., Lackey, T., Huang, Y., Bisping, E. H., Pu, W. T., Boxer, L. M., & Liang, Q. (2006) · The FASEB Journal · doi:10.1096/fj.05-5426fje · Cited by 116
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
Hasinoff, B. B., Patel, D., & Wu, X. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.08.005 · Cited by 115
Solem, L. E., Heller, L. J., & Wallace, K. B. (1996) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0095 · Cited by 111
Self-citationParker, M. A., King, V., & Howard, K. P. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00371-6 · Cited by 107
Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin
Palmeira, C. M., Serrano, J. A., Kuehl, D. W., & Wallace, K. B. (1997) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(97)00055-8 · Cited by 106
Self-citationOliveira, P. J., & Wallace, K. B. (2006) · Toxicology · doi:10.1016/j.tox.2005.12.009 · Cited by 105
Self-citationSardão, V. A., Oliveira, P. J., Holy, J. M., Oliveira, C. R., & Wallace, K. B. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0932-x · Cited by 103
Self-citationAscensão, A., Lumini-Oliveira, J., Machado, N. G., Ferreira, R. M., Gonçalves, I. O., Moreira, A. C., Marques, F., Sardão, V. A., Oliveira, P. J., & Magalhães, J. (2011) · Clinical Science · doi:10.1042/cs20100254 · Cited by 103
Self-citationDutta, D., Xu, J., Dirain, M. L. S., & Leeuwenburgh, C. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.011 · Cited by 103
Peng, Y., Jing, S., Liu, L., Ma, F., Zhang, Y., Wang, C., Duan, H., Zhou, K., Hua, Y., Wu, G., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206003 · Cited by 102
Berthiaume, J. M., Oliveira, P. J., Fariss, M. W., & Wallace, K. B. (2005) · Cardiovascular Toxicology · doi:10.1385/ct:5:3:257 · Cited by 101
Self-citationBerthiaume, J. M., & Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0026-0 · Cited by 99
Self-citationApoptosis in Isolated Adult Cardiomyocytes Exposed to Adriamycina
Kumar, D., Kirshenbaum, L. A., Li, T., Danelisen, I., & Singal, P. K. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09233.x · Cited by 99
Lozoya, O. A., Martínez‐Reyes, I., Wang, T., Grenet, D., Bushel, P. R., Li, J., Chandel, N. S., Woychik, R. P., & Santos, J. H. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005707 · Cited by 99
Kirkham, A. A., Shave, R., Bland, K. A., Bovard, J. M., Eves, N. D., Gelmon, K. A., McKenzie, D. C., Virani, S., Stöhr, E. J., Warburton, D. E. R., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.037 · Cited by 98
Mazat, J., Rossignol, R., Malgat, M., Rocher, C., Faustin, B., & Letellier, T. (2001) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(00)00236-x · Cited by 97
Arunachalam, S., Pichiah, P. B. T., & Achiraman, S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.11.019 · Cited by 96
Role of Lysines in Cytochrome c–Cardiolipin Interaction
Sinibaldi, F., Howes, B. D., Droghetti, E., Polticelli, F., Piro, M. C., Pierro, D. D., Fiorucci, L., Coletta, M., Smulevich, G., & Santucci, R. (2013) · Biochemistry · doi:10.1021/bi400324c · Cited by 95
Zhao, X., Jin, Y., Li, L., Xu, L., Tang, Z., Qi, Y., Yin, L., & Peng, J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104276 · Cited by 94
Mechanism of inhibition of mitochondrial enzymatic complex I–III by adriamycin derivatives
Goormaghtigh, E., Huart, P., Brasseur, R., & Ruysschaert, J. (1986) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(86)90406-2 · Cited by 89
Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.
Bennink, R. J., van den Hoff, M. J. B., van Hemert, F. J., de Bruin, K. M., Spijkerboer, A. L., Vanderheyden, J., Steinmetz, N. D., & van Eck‐Smit, B. L. F. (2004) · PubMed · Cited by 85
Berberine-induced cardioprotection and Sirt3 modulation in doxorubicin-treated H9c2 cardiomyoblasts
Coelho, A. R., Martins, T. R., Couto, R., Deus, C. M., Pereira, C. V., Simões, R. F., Rizvanov, A. A., Silva, F. S. G., Cunha‐Oliveira, T., Oliveira, P. J., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.030 · Cited by 83
Self-citationTranscriptional Control of Cardiac Fuel Metabolism and Mitochondrial Function
Leone, T. C., & Kelly, D. P. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.011965 · Cited by 81
Montaigne, D., Marechal, X., Préau, S., Baccouch, R., Modine, T., Fayad, G., Lancel, S., & Nevière, R. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.06.001 · Cited by 79
Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity
Jean, S. R., Tulumello, D. V., Riganti, C., Liyanage, S. U., Schimmer, A. D., & Kelley, S. O. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00268 · Cited by 79
Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity
Ferreira, A., Cunha‐Oliveira, T., Simões, R. F., Carvalho, F. S., Burgeiro, A., Nordgren, K. K. S., Wallace, K. B., & Oliveira, P. J. (2017) · Toxicology · doi:10.1016/j.tox.2017.08.011 · Cited by 79
Self-citationTokarska-Schlattner, M., Wallimann, T., & Schlattner, U. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.3.516 · Cited by 75
Jing, X., Yang, J., Jiang, L., Chen, J., & Wang, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491896 · Cited by 74
Abe, J., Yamada, Y., Takeda, A., & Harashima, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.024 · Cited by 73
Marechal, X., Montaigne, D., Marciniak, C., Marchetti, P., Hassoun, S. M., Beauvillain, J. C., Lancel, S., & Nevière, R. (2011) · Clinical Science · doi:10.1042/cs20110069 · Cited by 69
Exercise and Doxorubicin Treatment Modulate Cardiac Mitochondrial Quality Control Signaling
Marques‐Aleixo, I., Alves, E. S., Torrella, J. R., Oliveira, P. J., Magalhães, J., & Ascensão, A. A. M. R. (2017) · Cardiovascular Toxicology · doi:10.1007/s12012-017-9412-4 · Cited by 69
Self-citationWarren, J. S., Oka, S., Zablocki, D., & Sadoshima, J. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00103.2017 · Cited by 69
Tan, G., Lou, Z., Liao, W., Zhu, Z., Dong, X. W., Zhang, W., Li, W., & Chai, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027683 · Cited by 68
Mitochondrial health, the epigenome and healthspan
Aon, M. A., Cortassa, S., Juhaszova, M., & Sollott, S. J. (2016) · Clinical Science · doi:10.1042/cs20160002 · Cited by 66
Zhou, S., Heller, L. J., & Wallace, K. B. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9230 · Cited by 65
Self-citationCardiolipin dynamics and binding to conserved residues in the mitochondrial ADP/ATP carrier
Duncan, A. L., Ruprecht, J. J., Kunji, E. R. S., & Robinson, A. J. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.01.017 · Cited by 64
Doxorubicin‐induced cardiotoxicity involves IFNγ‐mediated metabolic reprogramming in cardiomyocytes
Chen, N., Ma, P., Wang, R., Lou, X., Liu, X., Qin, Y., Xue, R., Blasig, I. E., Erben, U., & Qin, Z. (2018) · The Journal of Pathology · doi:10.1002/path.5192 · Cited by 63
The anti-cancer drug doxorubicin induces substantial epigenetic changes in cultured cardiomyocytes
Hanf, A., Oelze, M. W., Manea, A., Li, H., Münzel, T. F., & Daiber, A. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108834 · Cited by 61
Faustin, B., Rossignol, R., Rocher, C., Bénard, G., Malgat, M., & Letellier, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314259200 · Cited by 60
Epigenetics in heart failure phenotypes
Berezin, A. Е. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.05.005 · Cited by 60
Moreira, A. C., Branco, A. F., Sampaio, S. F., Cunha‐Oliveira, T., Martins, T. R., Holy, J. M., Oliveira, P. J., & Sardão, V. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.09.015 · Cited by 59
Self-citationCardiovascular disease in survivors of childhood cancer
Bansal, N., Amdani, S. M., Hutchins, K. K., & Lipshultz, S. E. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000675 · Cited by 58
Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling
Ashley, N., & Poulton, J. (2009) · Oncogene · doi:10.1038/onc.2009.242 · Cited by 57
Nordgren, K. K. S., & Wallace, K. B. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.10.023 · Cited by 56
Self-citationHMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy
Luo, P., Zhu, Y., Chen, M., Yan, H., Yang, B., Yang, X., & He, Q. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.04.034 · Cited by 54
Cova, D., Angelis, L. D., Monti, E., & Piccinini, F. (1992) · Free Radical Research Communications · doi:10.3109/10715769209049151 · Cited by 53
Pereira, G. C., Pereira, S. P., Tavares, L. C., Carvalho, F. S., Novais, S. M., Barbosa, I. A., Santos, M. S., Bjork, J. A., Moreno, A. J., Wallace, K. B., et al. (2016) · Mitochondrion · doi:10.1016/j.mito.2016.07.005 · Cited by 53
Self-citationEffects of doxorubicin on cardiac muscle subsarcolemmal and intermyofibrillar mitochondria
Kavazis, A. N., Morton, A. B., Hall, S. E., & Smuder, A. J. (2016) · Mitochondrion · doi:10.1016/j.mito.2016.10.008 · Cited by 51
Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity
Wang, F., Iskra, B. S., Kleinerman, E. S., Alvarez‐Florez, C., Andrews, T. C., Shaw, A., Chandra, J., Schadler, K., & Aune, G. J. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001112 · Cited by 51
Cunha‐Oliveira, T., Ferreira, L. L., Coelho, A. R., Deus, C. M., & Oliveira, P. J. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.04.009 · Cited by 51
Self-citationBasal autophagy protects cardiomyocytes from doxorubicin-induced toxicity
Pizarro, M., Troncoso, R., Martínez, G. J., Chiong, M., Castro, P., & Lavandero, S. (2016) · Toxicology · doi:10.1016/j.tox.2016.09.011 · Cited by 49
Lue, Y., Gao, C., Swerdloff, R. S., Hoang, J., Avetisyan, R., Jia, Y., Rao, M., Ren, S. V., Atienza, V., Yu, J., et al. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00155.2018 · Cited by 49
Myocarditis Associated with Doxorubicin Cardiotoxicity
Gaudin, P. B., Hruban, R. H., Beschorner, W. E., Kasper, E. K., Olson, J. L., Baughman, K. L., & Hutchins, G. M. (1993) · American Journal of Clinical Pathology · doi:10.1093/ajcp/100.2.158 · Cited by 47
New iron chelators in anthracycline-induced cardiotoxicity
Mertlíková‐Kaiserová, H., Šimůnek, T., Štěrba, M., den Hartog, G. J. M., Schröterová, L., Popelová, O., Geršl, V., Kvasničková, E., & Bast, A. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0020-6 · Cited by 47
Niu, Q.-Y., Li, Z., Du, G., & Qin, X. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.10.026 · Cited by 46
Wang, X.-L., Wang, X., Xiong, L., Zhu, Y., Chen, H., Chen, J., Wang, X., Li, R., Guo, Z., Li, P., et al. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000009 · Cited by 46
Exercise Mitigates Cardiac Doxorubicin Accumulation and Preserves Function in the Rat
Jensen, B. T., Lien, C., Hydock, D. S., Schneider, C. M., & Hayward, R. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182982ce0 · Cited by 46
Yang, Y., Zhang, H., Li, X., Yang, T., & Jiang, Q. (2015) · PubMed · Cited by 45
A Metabolomic Study of Rats with Doxorubicin-Induced Cardiomyopathy and Shengmai Injection Treatment
Chen, Y., Tang, Y. M., Zhang, Y.-C., Huang, X.-H., Xie, Y.-Q., & Yin, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125209 · Cited by 42
Pereira, G. C., Pereira, S. P., Pereira, C. V., Lumini‐Oliveira, J., Magalhães, J., Ascensão, A. A. M. R., Santos, M. S., Moreno, A. J., & Oliveira, P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038867 · Cited by 42
Self-citationVoest, E. E., van Acker, S. A. B. E., van der Vijgh, W. J. F., van Asbeck, B. S., & Bast, A. (1994) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1994.1136 · Cited by 42
Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F1 mice
Schnackenberg, L. K., Pence, L. M., Vijay, V., Moland, C. L., George, N. I., Cao, Z., Yu, L., Fuscoe, J. C., Beger, R. D., & Desai, V. G. (2016) · Journal of Applied Toxicology · doi:10.1002/jat.3307 · Cited by 40
Deus, C. M., Zehowski, C., Nordgren, K. K. S., Wallace, K. B., Skildum, A. J., & Oliveira, P. J. (2015) · Toxicology · doi:10.1016/j.tox.2015.05.001 · Cited by 39
Self-citationKametani, R., Miura, T., Harada, N., Shibuya, M., Wang, R., Tan, H., Fukagawa, Y., Kawamura, S., & Matsuzaki, M. (2006) · Circulation Journal · doi:10.1253/circj.70.321 · Cited by 39
UVRAG Deficiency Exacerbates Doxorubicin-Induced Cardiotoxicity
An, L. K., Hu, X., Zhang, S., Hu, X., Song, Z., Naz, A., Zi, Z., Wu, J., Li, C., Zou, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep43251 · Cited by 39
Juárez‐Flores, D. L., González‐Casacuberta, I., Ezquerra, M., Bañó, M., Carmona, F., Catalán‐García, M., Guitart‐Mampel, M., Rivero, J. J., Tobías, E., Milisenda, J. C., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1526-3 · Cited by 37
Sampaio, S. F., Branco, A. F., Wojtala, A., Vega‐Naredo, I., Wieckowski, M. R., & Oliveira, P. J. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1583-9 · Cited by 33
Self-citationSkildum, A. J., Dornfeld, K. J., & Wallace, K. B. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1268-2 · Cited by 32
Self-citationBae, S., Siu, P. M., Choudhury, S., Ke, Q., Choi, J. H., Koh, Y. Y., & Kang, P. M. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00168.2010 · Cited by 32
Piotrowska, I., Isalan, M., & Mielcarek, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180571 · Cited by 31
Wang, H., Wang, H., Liang, E., Zhou, L., Zhan-ling, D., Liang, P., Qi-fang, W., & Yang, M. (2017) · Oncology Letters · doi:10.3892/ol.2017.7410 · Cited by 31
Chen, Z., Chen, L., & Cheng, J. (2013) · PPAR Research · doi:10.1155/2013/456042 · Cited by 29
Pereira, C. V., Oliveira, P. J., Will, Y., & Nadanaciva, S. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.07.030 · Cited by 28
Self-citationCarvedilol Inhibits the Mitochondrial Permeability Transition by an Antioxidant Mechanism
Oliveira, P. J., Esteves, T. C., Rolo, A. P., Palmeira, C. M., & Moreno, A. J. (2004) · Cardiovascular Toxicology · doi:10.1385/ct:4:1:11 · Cited by 27
Self-citationEffects of Resistance Exercise Training on Doxorubicin-Induced Cardiotoxicity
Pfannenstiel, K., & Hayward, R. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000574 · Cited by 26
Effects of Calorie Restriction and Voluntary Exercise on Doxorubicin-Induced Cardiotoxicity
Hall, S. E., Smuder, A. J., & Hayward, R. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419843999 · Cited by 25
Oliveira, P. J., Rolo, A. P., Palmeira, C. M., & Moreno, A. J. (2001) · Cardiovascular Toxicology · doi:10.1385/ct:1:3:205 · Cited by 24
Self-citationYang, Y., Zhang, H., Li, X., Yang, T., & Jiang, Q. (2014) · PubMed Central · Cited by 22
Zhao, Y. X., Tian, X., Liu, G., Wang, K., Xie, Y., & Qiu, Y. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6949 · Cited by 22
Cocco, T., Cutecchia, G., Montedoro, G., & Lorusso, M. P. (2002) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1020248300766 · Cited by 21
Tarr, M., & van Helden, P. D. (1990) · Molecular and Cellular Biochemistry · doi:10.1007/bf00226185 · Cited by 16
Cited by
Wang, Y., Yan, S., Liu, X., Deng, F., Wang, P., Yang, L., Hu, L., Huang, K., & He, J. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00990-5 · Cited by 315
Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity
Lei, Y., VanPortfliet, J. J., Chen, Y.-F., Bryant, J. D., Li, Y., Fails, D., Torres-Odio, S., Ragan, K. B., Deng, J., Mohan, A., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.039 · Cited by 289
Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches
Heymans, S., Lakdawala, N. K., Tschöpe, C., & Klingel, K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01241-2 · Cited by 267
Wu, L., Wang, L., Du, Y., Zhang, Y., & Ren, J. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.10.003 · Cited by 257
Telomerase therapy attenuates cardiotoxic effects of doxorubicin
Chatterjee, S., Hofer, T., Costa, A., Lu, D., Batkai, S., Gupta, S. K., Bolesani, E., Zweigerdt, R., Megias, D., Streckfuss-Bömeke, K., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.035 · Cited by 63
“Doxorubicin toxicity is also attributed to the generation of ROS.(21,22) In order to detect ROS production, we applied the Amplex Red reagent as it reacts with extracellular H2O2 in the presence of horseradish peroxidase, to produce highly fluorescent resorufin.”
MethodInfluential
Metadata
- Authors
- Wallace, K. B., Sardão, V. A., & Oliveira, P. J.
- Venue
- Circulation Research
- Published
- 2020-03-27
- Volume
- 126
- Issue
- 7
- Pages
- 926-941
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W3013813924
- Cited by
- 599
- References
- 164
- FWCI
- 41.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.